Twist Bioscience stock posts Q4 growth, guides for fiscal 2027

Twist Bioscience announced its fiscal fourth-quarter and full-year 2026 results on Thursday, November 12, 2026. Revenue increased 28% year over year to 126.6 million US dollars in the quarter, while adjusted EBITDA reached 2.2 million US dollars. The company still recorded a net loss of 20.6 million US dollars, or 0.32 US dollars per diluted share.

The results were published in Twist Bioscience's fiscal results release. Gross margin increased to 53.1% from 51.3% a year earlier. DNA Synthesis and Protein Solutions revenue rose 33% to 61.0 million US dollars, while NGS Applications revenue gained 24% to 65.7 million US dollars.

Guidance points to continued growth

For fiscal 2027, Twist expects revenue between 550 million and 560 million US dollars, with gross margin of 52.5% to 53% and positive adjusted EBITDA. First-quarter fiscal 2027 revenue is expected to range from 130 million to 132 million US dollars.

Full-year fiscal 2026 revenue reached 459.4 million US dollars, up from 376.6 million US dollars in fiscal 2025. The company reported a fiscal-year net loss of 130.2 million US dollars and held approximately 582 million US dollars in cash, cash equivalents and short-term investments at September 30, 2026.

Twist's fiscal 2026 results arrived alongside continued investment in capacity, automation and new products. The company said its fiscal 2027 outlook assumes 100 million US dollars of revenue from AI drug discovery.

The broader US market context is available through current Nasdaq Composite coverage.

More news and analyses on Twist Bioscience stock